Melanoma Molecular Maps Projects



Title: c-MYC pathways
Legend: The c-Myc proto-oncogene encodes a prototypical oncogenic transcription factor that is believed to play a central role in the genesis of many different human cancers, including melanoma. c-Myc acts as a heterodimer with MAX; its biological functions are numerous as it is believed to affect the transciption of as much as 15% of all human genes. CITED MOLECULES: Akt (protein kinase B, PKB), ASK1 (MAP3K5, mitogen-activated protein kinase kinase kinase 5), Bcl-2 (B-cell CLL/lymphoma 2), beta-catenin, Blimp-1 (PRDM1), Bortezomib, BRAF (mitogen activated protein kinase [MAPK] kinase kinase, MAP3K), BRAF V600E (mutated BRAF), CDK4 (cyclin dependent kinase 4), c-Fos, c-Met (hepatocyte growth factor [HGF] receptor), c-Myc, Cyclin A2, Cyclin D2, Cyclin E1, Cisplatin, Doxorubicin, DUSP1 (dual specificity phosphatase 1), E2F (transcription factor), E3 ligase, EIF4E (eukaryotic translation initiation factor 4E), ERBB2 (HER2/neu), ERG (v-ets erythroblastosis viral oncogene homolog), ERK (MAPK), ERK1, ERK2, Fibronectin-1, Gadd45 (growth arrest and DNA damage inducible), GSK3 (glycogen synthase kinase 3), HAT (histone acetyl-transferase), HDAC (histone deacetylase), HDM2 (Mdm2 p53 binding protein homolog), HIF1 (hypoxia inducible factor 1), HSP60 (heat shock protein 60), HSP70, HSP90, hTERT (human telomerase), IFN-beta (interferon beta), Let-7a (microRNA), MAD (MAX dimerization protein, MXD), MAX (MYC associated factor X), MEK (MAP2K), MEK1, MEK2, MEK3, MEK6, mir-17-3p, mir-17-5p, mir-18, mir-19a, mir-19b-1, mir-20, mir-92-1, mir-17-92 cluster, MITF (microphthalmia associated transcription factor), MLH1 (mutL protein homolog 1), MMP2 (matrix metalloproteinase 2), MNT (Max-binding protein MNT), MSH2 (MutS protein homolog 2), NOXA, NRAS Q61R (mutated NRAS), ODC1 (ornithine decarboxylase 1), p14ARF (CDKN2A locus alternative reading frame), p21 (Cip1/Waf1), p38 (MAPK14), p53, PHLPP (PH domain leucine-rich repeat protein phosphatase), PNPT1 (polyribonucleotide nucleotidyltransferase 1 ), Proteasome, PUMA (p53 upregulated modulator of apoptosis, BBC3), RAF (v-Raf oncogene homolog), RAS (v-Ras oncogene homolog), RPL3 (ribosomal protein L3), RPL6, RPL23, SRM (spermidine synthase), Survivin, TAK1 (TGF-beta activated kinase 1, MAP3K7), TRRAP (transformation/transcription domain-associated protein), VEGF (vascular endothelial growth factor), WS5. REFERENCES: [1] Wierstra I, Adv Cancer Res 2008, 99:113-333. [2] Prochownik EV, Curr Mol Med 2008, 8:446-58. [3] Knoepfler PS, Cancer Res 2007, 67:5061-3. [4] Bosserhoff AK, Clin Chim Acta 2006, 367:28-35.
Author: Albert Dobi, Rockville, MD, USA (December 2008)

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

NCBI's Disclaimer and Copyright notice